Alvotech (ALVO) Stock Price, News & Analysis

Company Overview

Alvotech is a biopharmaceutical company headquartered in Reykjavik, Iceland, focused on developing and manufacturing biosimilar medicines. Its products are intended to provide alternatives to biologic therapies used to treat conditions including autoimmune diseases, cancer and eye disorders.

The company has established a pipeline spanning several therapeutic areas, with candidates targeting medicines such as ustekinumab, denosumab, secukinumab and aflibercept. Alvotech operates an integrated platform covering cell-line development, process development, analytical testing and commercial-scale manufacturing.

Founded in 2013, Alvotech serves international markets through commercial and strategic partnerships. Its agreements have included collaborations with Teva Pharmaceuticals and other regional pharmaceutical companies, supporting the registration, distribution and commercialization of its biosimilars in markets including the United States, Europe, Japan and emerging markets.

Key Stats

• Today's Range: $5.68 to $6.17
• 50-Day Range: $3.06 to $6.15
• 52-Week Range: $2.94 to $9.05
• Volume: 1.43 million shs
• Average Volume: 1.10 million shs
• Market Capitalization: $1.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Alvotech Stock Analysis - MarketRank™

Alvotech scored higher than 79% of companies evaluated by MarketBeat, and ranked 109th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alvotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Alvotech has a consensus price target of $8.50, representing about 38.2% upside from its current price of $6.15.

Amount of Analyst Coverage

Alvotech has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 2,300.00%

Earnings Growth

Earnings for Alvotech are expected to grow by 2,300.00% in the coming year, from $0.01 to $0.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alvotech is -10.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alvotech is -10.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.93% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 8.84.

Change versus previous month

Short interest in Alvotech has recently increased by 4.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alvotech does not currently pay a dividend.

Dividend Growth

Alvotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.23

News Sentiment

Alvotech has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Alvotech this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for ALVO on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alvotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alvotech insiders have not sold or bought any company stock.

Percentage Held by Institutions

Alvotech has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/20/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALVO
• Previous Symbol: NYSE:ALVO
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354-422-4500
• Fax: N/A
• Employees: 1,460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alvotech: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +38.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 615.00
• P/E Growth: N/A
• Net Income: $27.92 million
• Net Margins: -36.31%
• Pretax Margin: 23.25%
• Return on Equity: -11.92%
• Return on Assets: -11.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $588.90 million
• Price / Sales: 3.15
• Cash Flow: $0.23 per share
• Price / Cash Flow: 26.39
• Book Value: ($0.94) per share
• Price / Book: -6.54

Miscellaneous

• Outstanding Shares: 301,810,000
• Free Float: N/A
• Market Cap: $1.86 billion
• Optionable: Not Optionable
• Beta: 0.22